{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:51:07Z","timestamp":1771487467977,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Spanish Ministry of Health","award":["CP16\/00041"],"award-info":[{"award-number":["CP16\/00041"]}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["10147"],"award-info":[{"award-number":["10147"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIA Grant","award":["AG-10124"],"award-info":[{"award-number":["AG-10124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12035-018-1313-4","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T02:00:49Z","timestamp":1534903249000},"page":"3476-3483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cerebrospinal Fluid Total and Phosphorylated \u03b1-Synuclein in Patients with Creutzfeldt\u2013Jakob Disease and Synucleinopathy"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-681X","authenticated-orcid":false,"given":"Matthias","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Villar-Piqu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Gmitterov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Varges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leentje","family":"Demeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Q","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia M-Y","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"10","key":"1313_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1212\/WNL.38.10.1520","volume":"38","author":"CR Burkhardt","year":"1988","unstructured":"Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA (1988) Diffuse Lewy body disease and progressive dementia. Neurology 38(10):1520\u20131528","journal-title":"Neurology"},{"issue":"5","key":"1313_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00005072-198809000-00005","volume":"47","author":"T Yamamoto","year":"1988","unstructured":"Yamamoto T, Imai T (1988) A case of diffuse Lewy body and Alzheimer\u2019s diseases with periodic synchronous discharges. J Neuropathol Exp Neurol 47(5):536\u2013548","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1313_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1017\/S0317167100013421","volume":"39","author":"MC Tartaglia","year":"2012","unstructured":"Tartaglia MC, Johnson DY, Thai JN, Cattaruzza T, Wong K, Garcia P, Dearmond SJ, Miller BL et al (2012) Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci 39(3):304\u2013310","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"1313_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89(1):88\u2013100. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004058","journal-title":"Neurology"},{"issue":"5","key":"1313_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","volume":"12","author":"F Llorens","year":"2016","unstructured":"Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, Varges D, Schmidt C et al (2016) Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement 12(5):577\u2013589. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2015.10.009","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1313_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jalz.2016.09.013","volume":"13","author":"F Llorens","year":"2017","unstructured":"Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thune K, Zejneli O, Kanata E et al (2017) Evaluation of alpha-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. Alzheimers Dement 13(6):710\u2013719. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2016.09.013","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1313_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ana.410430109","volume":"43","author":"I Zerr","year":"1998","unstructured":"Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA et al (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43(1):32\u201340. \n                    https:\/\/doi.org\/10.1002\/ana.410430109","journal-title":"Ann Neurol"},{"issue":"47","key":"1313_CR8","first-page":"361","volume":"73","author":"WHO","year":"1998","unstructured":"WHO (1998) Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec 73(47):361\u2013365","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"1313_CR9","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1007\/s12035-015-9133-2","volume":"53","author":"M Cramm","year":"2016","unstructured":"Cramm M, Schmitz M, Karch A, Mitrova E, Kuhn F, Schroeder B, Raeber A, Varges D et al (2016) Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol 53(3):1896\u20131904. \n                    https:\/\/doi.org\/10.1007\/s12035-015-9133-2","journal-title":"Mol Neurobiol"},{"issue":"11","key":"1313_CR10","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/nprot.2016.120","volume":"11","author":"M Schmitz","year":"2016","unstructured":"Schmitz M, Cramm M, Llorens F, Muller-Cramm D, Collins S, Atarashi R, Satoh K, Orru CD et al (2016) The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc 11(11):2233\u20132242. \n                    https:\/\/doi.org\/10.1038\/nprot.2016.120","journal-title":"Nat Protoc"},{"issue":"4","key":"1313_CR11","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s12035-015-9167-5","volume":"53","author":"M Schmitz","year":"2016","unstructured":"Schmitz M, Ebert E, Stoeck K, Karch A, Collins S, Calero M, Sklaviadis T, Laplanche JL et al (2016) Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol Neurobiol 53(4):2189\u20132199. \n                    https:\/\/doi.org\/10.1007\/s12035-015-9167-5","journal-title":"Mol Neurobiol"},{"issue":"10","key":"1313_CR12","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00415-015-7837-x","volume":"262","author":"F Llorens","year":"2015","unstructured":"Llorens F, Kruse N, Schmitz M, Shafiq M, da Cunha JE, Gotzman N, Zafar S, Thune K et al (2015) Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD. J Neurol 262(10):2305\u20132311. \n                    https:\/\/doi.org\/10.1007\/s00415-015-7837-x","journal-title":"J Neurol"},{"issue":"10","key":"1313_CR13","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","volume":"15","author":"P Oeckl","year":"2016","unstructured":"Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P, Ludolph AC, Otto M (2016) Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics 15(10):3126\u20133138. \n                    https:\/\/doi.org\/10.1074\/mcp.M116.059915","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"1313_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00415-014-7334-7","volume":"261","author":"T Kasai","year":"2014","unstructured":"Kasai T, Tokuda T, Ishii R, Ishigami N, Tsuboi Y, Nakagawa M, Mizuno T, El-Agnaf OM (2014) Increased alpha-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 261(6):1203\u20131209. \n                    https:\/\/doi.org\/10.1007\/s00415-014-7334-7","journal-title":"J Neurol"},{"issue":"10","key":"1313_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, Calabresi P, Parnetti L (2017) Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 32(10):1389\u20131400. \n                    https:\/\/doi.org\/10.1002\/mds.27110","journal-title":"Mov Disord"},{"issue":"9","key":"1313_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00207454.2014.961454","volume":"125","author":"L Gao","year":"2015","unstructured":"Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R et al (2015) Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 125(9):645\u2013654. \n                    https:\/\/doi.org\/10.3109\/00207454.2014.961454","journal-title":"Int J Neurosci"},{"key":"1313_CR17","doi-asserted-by":"publisher","first-page":"567386","DOI":"10.1155\/2015\/567386","volume":"2015","author":"B Zhou","year":"2015","unstructured":"Zhou B, Wen M, Yu WF, Zhang CL, Jiao L (2015) The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha -synuclein levels in Parkinson\u2019s disease: a meta-analysis. Parkinsons Dis 2015:567386\u2013567311. \n                    https:\/\/doi.org\/10.1155\/2015\/567386","journal-title":"Parkinsons Dis"},{"key":"1313_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S et al (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener 11:7. \n                    https:\/\/doi.org\/10.1186\/s13024-016-0072-9","journal-title":"Mol Neurodegener"},{"issue":"121","key":"1313_CR19","doi-asserted-by":"publisher","first-page":"121ra120","DOI":"10.1126\/scitranslmed.3002566","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ et al (2012) Phosphorylated alpha-synuclein in Parkinson\u2019s disease. Sci Transl Med 4(121):121ra120. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3002566","journal-title":"Sci Transl Med"},{"issue":"Pt 10","key":"1313_CR20","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1093\/brain\/awp191","volume":"132","author":"I Zerr","year":"2009","unstructured":"Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132(Pt 10):2659\u20132668. \n                    https:\/\/doi.org\/10.1093\/brain\/awp191","journal-title":"Brain"},{"issue":"12","key":"1313_CR21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22(12):1689\u20131707; quiz 1837. \n                    https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"issue":"1","key":"1313_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","volume":"9","author":"D Chiasserini","year":"2017","unstructured":"Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N et al (2017) Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia. Alzheimers Res Ther 9(1):52. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0276-4","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"1313_CR23","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics 12(12):3543\u20133558. \n                    https:\/\/doi.org\/10.1074\/mcp.R113.032730","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"1313_CR24","doi-asserted-by":"publisher","first-page":"430 e431","DOI":"10.1016\/j.neurobiolaging.2010.12.001","volume":"33","author":"MB Aerts","year":"2012","unstructured":"Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33(2):430 e431\u2013430 e433. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.12.001","journal-title":"Neurobiol Aging"},{"issue":"3","key":"1313_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nagga K, Londos E et al (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res Ther 6(3):25. \n                    https:\/\/doi.org\/10.1186\/alzrt255","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1313_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JAD-2010-100186","volume":"22","author":"FE Reesink","year":"2010","unstructured":"Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P et al (2010) CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer\u2019s disease. J Alzheimers Dis 22(1):87\u201395. \n                    https:\/\/doi.org\/10.3233\/JAD-2010-100186","journal-title":"J Alzheimers Dis"},{"issue":"5\u20138","key":"1313_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13195-014-0072-3","volume":"6","author":"S Schade","year":"2014","unstructured":"Schade S, Mollenhauer B (2014) Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther 6(5\u20138):72. \n                    https:\/\/doi.org\/10.1186\/s13195-014-0072-3","journal-title":"Alzheimers Res Ther"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnagi.2014.00198","volume":"6","author":"F Llorens","year":"2014","unstructured":"Llorens F, Lopez-Gonzalez I, Thune K, Carmona M, Zafar S, Andreoletti O, Zerr I, Ferrer I (2014) Subtype and regional-specific neuroinflammation in sporadic Creutzfeldt-Jakob disease. Front Aging Neurosci 6:198. \n                    https:\/\/doi.org\/10.3389\/fnagi.2014.00198","journal-title":"Front Aging Neurosci"},{"key":"1313_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","volume":"200","author":"G Muntane","year":"2012","unstructured":"Muntane G, Ferrer I, Martinez-Vicente M (2012) Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106\u2013119. \n                    https:\/\/doi.org\/10.1016\/j.neuroscience.2011.10.042","journal-title":"Neuroscience"},{"issue":"6","key":"1313_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/jnnp.2007.134163","volume":"7","author":"I McKeith","year":"2007","unstructured":"McKeith I (2007) Dementia with Lewy bodies and Parkinson\u2019s disease with dementia: where two worlds collide. Pract Neurol 7(6):374\u2013382. \n                    https:\/\/doi.org\/10.1136\/jnnp.2007.134163","journal-title":"Pract Neurol"},{"issue":"1","key":"1313_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16(1):55\u201365. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(16)30291-5","journal-title":"Lancet Neurol"},{"key":"1313_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","volume":"3","author":"T Stewart","year":"2015","unstructured":"Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP et al (2015) Phosphorylated alpha-synuclein in Parkinson\u2019s disease: correlation depends on disease severity. Acta Neuropathol Commun 3:7. \n                    https:\/\/doi.org\/10.1186\/s40478-015-0185-3","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"1313_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11095-005-9045-3","volume":"23","author":"JW Lee","year":"2006","unstructured":"Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2):312\u2013328. \n                    https:\/\/doi.org\/10.1007\/s11095-005-9045-3","journal-title":"Pharm Res"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1313-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T20:38:26Z","timestamp":1569962306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1313-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1313-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The present study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and has been approved by the local ethics committee in the University Medical Center, G\u00f6ttingen (No. 9\/6\/08, 19\/11\/09, and 18\/8\/15). Informed consent was given by all study participants or their legal next of kin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The full databank of the data is available to each co-author on the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Leentje Demeyer and Erik Stoops are employees of ADx NeuroSciences. Hugo Vanderstichele is a co-founder of ADx NeuroSciences and a founder of Biomarkable. All other authors declare there are no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}